Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Tetrazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrazole SCHEMBL29614407 | 1.00 | — | — | |
| Tetrazole SCHEMBL6130450 | 1.00 | — | — | |
| Tetrazole SCHEMBL6130451 | 1.00 | — | — | |
| Tetrazole SCHEMBL21856 | 1.00 | — | — | |
| Tetrazole SCHEMBL7089941 | 1.00 | — | — | |
| Tetrazole SCHEMBL29129825 | 0.97 | — | — | |
| Tetrazole SCHEMBL1012000 | 0.97 | — | — | |
| Tetrazole SCHEMBL27496331 | 0.97 | — | — | |
| Tetrazole SCHEMBL27706177 | 0.97 | — | — | |
| Tetrazole SCHEMBL17874201 | 0.96 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190117678-A1 | Method of Treating Acute Coronary Syndromes | ZULI HOLDINGS LTD. (IL) | 2019-04-25 | — | — | US | disclosed |
| EP-2266536-B9 | Method of treating acute myocardial infarction | BIOREST LTD (IL) | 2018-05-16 | — | — | EP | disclosed |
| US-20180055860-A1 | Method of Treating Acute Coronary Syndromes | ZULI HOLDINGS LTD. (IL) | 2018-03-01 | — | — | US | disclosed |
| US-9827254-B2 | Method of treating acute coronary syndromes | BIOREST LTD. (IL) | 2017-11-28 | — | — | US | disclosed |
| EP-2266536-B1 | Method of treating acute myocardial infarction | BIOREST LTD (IL) | 2017-08-23 | — | — | EP | disclosed |
| US-20170100415-A1 | Method of Treating Acute Coronary Syndromes | ZULI HOLDINGS LTD. (IL) | 2017-04-13 | — | — | US | disclosed |
| US-9498488-B2 | Method of treating acute coronary syndromes | BIOREST LTD. | 2016-11-22 | — | — | US | disclosed |
| EP-1643982-B1 | METHOD OF TREATING ACUTE MYOCARDIAL INFARCTION | BIOREST LTD (IL) | 2015-09-23 | — | — | EP | disclosed |
| CN-1842323-B | Method of treating ischemia-reperfusion injury | BIOREST LTD | 2012-08-08 | — | — | CN | disclosed |
| EP-2266536-A2 | Method of treating acute myocardial infarction | Biorest Ltd. (IL) | 2010-12-29 | — | — | EP | disclosed |
| EP-1638526-A1 | METHOD OF TREATING ACUTE CORONARY SYNDROMES | Biorest Ltd. (IL) | 2006-03-29 | — | — | EP | disclosed |
| US-20060051407-A1 | administering encapsulated drugs which inhibits and/or depletes phagocytic cells with high specificity, thereby suppressing the inflammatory response that occurs during and following acute myocardial infarction; cardiovascular disorders | BIOREST LTD. (IL) | 2006-03-09 | — | — | US | disclosed |
| WO-2005013948-A2 | METHOD OF TREATING ACUTE MYOCARDIAL INFARCTION | BIOREST LTD. (IL) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005002545-A1 | METHOD OF TREATING ACUTE CORONARY SYNDROMES | BIOREST LTD. (IL) | 2005-01-13 | — | — | WO | disclosed |
| US-20040265391-A1 | Method of treating acute myocardial infarction | ZULI HOLDINGS LTD. (IL) | 2004-12-30 | — | — | US | disclosed |
| US-20040266734-A1 | administering encapsulated bisphosphonate or gallium which inhibits and/or depletes phagocytic cells with high specificity, thereby suppressing the inflammatory response that occurs during and following myocardium necrosis; cardiovascular disorders | ZULI HOLDINGS LTD. (IL) | 2004-12-30 | — | — | US | disclosed |
| US-6670138-B2 | Diagnosing and detecting stroke in humans; obtain tissue sample, detect expression of uncoupling proteins, evaluate for stroke | AGY THERAPEUTICS, INC. | 2003-12-30 | — | — | US | disclosed |
| EP-1330548-A2 | METHODS OF DIAGNOSING, PREVENTING AND TREATING NEUROLOGICAL DISORDERS AND NEURONAL INJURIES | Agy Therapeutics, Inc. (US) | 2003-07-30 | — | — | EP | disclosed |
| US-20020172958-A1 | Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries | AGY THERAPEUTICS, INC. (US) | 2002-11-21 | — | — | US | disclosed |
| WO-2002036829-A2 | METHODS OF DIAGNOSING, PREVENTING AND TREATING NEUROLOGICAL DISORDERS AND NEURONAL INJURIES | AGY THERAPEUTICS, INC. (US) | 2002-05-10 | — | — | WO | disclosed |